Abstract: The present invention is concerned with a modified release pharmaceutical composition comprising an effective amount of at least one antipsychotic agent so that the antipsychotic agent(s) are released in such a manner to better accord with physiological and chronotherapeutic requirements of patients.

Abstract: A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.

Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Abstract: Disclosed herein is the use of an extract from Alpinia spp. for the preparation of a medicament for the treatment of irritable bowel syndrome (IBS). The extract is prepared by extracting fresh and/or dried fruits of Alpinia spp. plant with a solvent such as a supercritical fluid, water, 10-95% (v/v) ethanol, acetone, ethyl acetate or n-hexane, to obtain an extract suitable for the preparation of IBS medicaments. In some embodiments, active compounds with anti-abnormal defecation activity and/or analgesia effect are isolated from the water extract of Alpinia spp.; these compounds are therefore potential lead compounds for use as medicaments for treating IBS.

Abstract: Disclosed herein is the use of an extract from an Aster species for the preparation of a medicament for the treatment of opioid-induced constipation. The extract is extracted from fresh and/or dried roots and rhizomes of a Tatarian aster (Aster tartaricus) plant, in which the extraction uses water or 40-95% (v/v) ethanol as an extractant to obtain an extraction mixture. In some embodiments, the extraction mixture is then eluted with water followed by at least one eluent.

Abstract: A vitamin K2 microsphere. The microsphere includes a poly(lactide-co-glycolide) acid (PLGA) particle, in which the Mw of PLGA is between 1000 and 300000, and the molar ratio between the lactide repeat units and the glycolide repeate unit is 1-9:9-1; and one or more vitamin K2 molecules are embedded in the PLGA particle, wherein the vitamin K2 is present in an amount of 0.005-75 wt %, based on the weight of the microsphere. Also disclosed are a method of preparing the vitamin K2 microsphere, a method of treating osteoporosis using this microsphere, and a pharmaceutical composition containing the microsphere.

Abstract: A new use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori such as gastritis, gastric ulcer or duodenal ulcer in a patient. The potent product is prepared by a process including the steps of a) preparing a crude extract from rhizomes of Zingiber officinale, said crude extract comprising 6-gingerol and 6-shogaol; b) introducing the crude extract to a normal phase chromatography column, and eluting the column with a first eluent having a polarity lower than that of a mixture of n-hexane and ethyl acetate in a weight ratio of 6:4 to obtain a potent fraction. Preferably, the potent fraction is substantially free of both 6-gingerol and 6-shogaol.

Abstract: An antitussive composition is provided. A pharmaceutical composition for relieving, preventing and/or treating a cough includes a sufficient amount of the Morus australis Poir extract as an active component. The effective Morus australis Poir extract is prepared by extracting the root-bark of the Morus australis Poir with water, ethanol, acetone, ethyl acetate, or a combination thereof. The crude extract can be further fractioned by ultrafiltration or reverse phase column.

Abstract: A method of preparing a taste-masking oral dosage form is provided. The method includes providing a first solution comprising a pharmaceutically active ingredient and a starch, providing a second solution comprising a hydrophilic polymer and a surfactant, blending the first and second solution to form a plurality of microparticles by a granulating process, wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch, and performing a compression-molding process to form the tablet.

Abstract: An extract prepared from the root barks of Morus australis Poir.

Abstract: A new use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori such as gastritis, gastric ulcer or duodenal ulcer in a patient. The potent product is prepared by a process including the steps of a) preparing a crude extract from rhizomes of Zingiber officinale, said crude extract comprising 6-gingerol and 6-shogaol; b) introducing the crude extract to a normal phase chromatography column, and eluting the column with a first eluent having a polarity lower than that of a mixture of n-hexane and ethyl acetate in a weight ratio of 6:4 to obtain a potent fraction. Preferably, the potent fraction is substantially free of both 6-gingerol and 6-shogaol.

Abstract: The present invention discloses a new use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori such as gastritis, gastric ulcer or duodenal ulcer in a patient. The potent product is prepared by a process including the steps of a) preparing a crude extract from rhizomes of Zingiber officinale, said crude extract comprising 6-gingerol and 6-shogaol; b) introducing the crude extract to a reverse phase chromatography column, and eluting the column with a first eluent having a polarity lower than water to obtain a first potent fraction or a second eluent having a polarity lower than that of the first eluent to obtain a second potent fraction. Preferably, the second potent fraction is substantially free of both 6-gingerol and 6-shogaol.

Abstract: The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H1 receptor antagonism effect in a patient to treat a disease or disorder, such as allergy.

Abstract: An extract prepared from the root barks of Morus australis Poir.

Abstract: A composite dressing including a first polymeric layer, a second polymeric layer, a metal oxide, and a pharmaceutical active material is provided. The second polymeric layer is biocompatible and is disposed on a surface of the first polymeric layer. The metal oxide is distributed inside or on at least one surface of the first polymeric layer, while the pharmaceutical active material is distributed inside or on at least one surface of the second polymeric layer.

Abstract: A polygalatenoside useful as an antidepressant agent having the formula is disclosed: wherein R, R? and R? independently are H or R1, provided that R, R? and R? are not all H, wherein R1 is wherein R2 is hydrogen, C1-C6 alkyl, C1-C6 alkoxy or halogen; or a pharmaceutically acceptable salt thereof. Preferably, R2 is H.

Abstract: The present invention discloses a new use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori such as gastritis, gastric ulcer or duodenal ulcer in a patient. The potent product is prepared by a process including the steps of a) preparing a crude extract from rhizomes of Zingiber officinale, said crude extract comprising 6-gingerol and 6-shogaol; b) introducing the crude extract to a reverse phase chromatography column, and eluting the column with a first eluent having a polarity lower than water to obtain a first potent fraction or a second eluent having a polarity lower than that of the first eluent to obtain a second potent fraction. Preferably, the second potent fraction is substantially free of both 6-gingerol and 6-shogaol.

Abstract: The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H1 receptor antagonism effect in a patient to treat a disease or disorder, such as allergy.

Abstract: A porous dressing is provided. The porous dressing includes a polymeric layer, a pharmaceutically active ingredient and a metal oxide. The polymeric layer has a porosity and a bio-compatibility, and the pharmaceutically active ingredient and the metal oxide distribute in one selected from a group consisting of in the polymeric layer, on a surface of the polymeric layer and a combination thereof.

Abstract: A polygalatenoside useful as an antidepressant agent having the formula is disclosed: wherein R, R? and R? independently are H or R1, provided that R, R? and R? are not all H, wherein R1 is wherein R2 is hydrogen, C1-C6 alkyl, C1-C6 alkoxy or halogen; or a pharmaceutically acceptable salt thereof. Preferably, R2 is H.